Experts see tolebrutinib as part of a broader shift toward treatments that target the neurodegeneration in MS, not just its ...

Fenebrutinib significantly reduced new lesions with active inflammation in people with relapsing MS in a Phase 2 trial.

Sanofi SNY reported second-quarter 2025 adjusted earnings of 90 cents per American depositary share, which missed the Zacks ...

In 2025, sales are anticipated to grow by a high single-digit percentage at CER (previously mid-to-high single-digit). Sanofi confirms the expectation of a strong business EPS rebound with growth at a ...

A major scientific breakthrough has identified the Epstein-Barr virus (EBV) as the leading cause of multiple sclerosis (MS), ...

Sanofi completes acquisition of Blueprint Medicines Paris, July 18, 2025. Sanofi today announces the completion of its acquisition of Blueprint Medicines Corporation (Blueprint), adding to its ...

Following its acceptance of the tendered shares, Sanofi completed its acquisition of Blueprint through the merger of a wholly owned subsidiary of Sanofi with and into Blueprint, pursuant to ...

Sanofi, an R&D driven, AI-powered biopharma company, announces the completion of its acquisition of Blueprint Medicines Corporation (Blueprint), adding to its portfolio a commercialized medicine, a ...

Thermo Fisher will expand use of the Sanofi site to meet the demand from pharma and biotech customers for U.S. manufacturing capacity.

Sanofi announces extension of Blueprint tender offer Paris, July 17, 2025. Sanofi today announces that Rothko Merger Sub, Inc., a wholly owned subsidiary of Sanofi, has extended the expiration date ...

The clinical trial was sponsored by Sanofi, the developer of tolebrutinib. More information The Cleveland Clinic has more on tyrosine kinase inhibitors.